Last reviewed · How we verify
Vitamin C and Vitamin E
Vitamin C and Vitamin E act as antioxidants that neutralize free radicals and reduce oxidative stress in cells.
Vitamin C and Vitamin E act as antioxidants that neutralize free radicals and reduce oxidative stress in cells. Used for Antioxidant supplementation for oxidative stress reduction, General nutritional support.
At a glance
| Generic name | Vitamin C and Vitamin E |
|---|---|
| Also known as | Ascorbic acid and Tocopherol |
| Sponsor | Seoul National University Hospital |
| Drug class | Antioxidant vitamin combination |
| Modality | Small molecule |
| Therapeutic area | Nutritional supplementation / General wellness |
| Phase | FDA-approved |
Mechanism of action
Vitamin C (ascorbic acid) is a water-soluble antioxidant that donates electrons to neutralize reactive oxygen species and regenerate other antioxidants like vitamin E. Vitamin E (tocopherol) is a lipid-soluble antioxidant that protects cell membranes from oxidative damage. Together, they work synergistically to reduce cellular oxidative stress and inflammation.
Approved indications
- Antioxidant supplementation for oxidative stress reduction
- General nutritional support
Common side effects
- Gastrointestinal upset (nausea, diarrhea)
- Kidney stone formation (high-dose vitamin C)
- Headache
Key clinical trials
- Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women (PHASE1)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1 (NA)
- Structured Review: To Optimise Management and Prevent Harm in COPD (NA)
- A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (NA)
- A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D) (NA)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin C and Vitamin E CI brief — competitive landscape report
- Vitamin C and Vitamin E updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI